GeneDx (WGS) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Speaker0Day and thank you for standing by. Welcome to the GeneDx Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To withdraw your question, please press ...

Core Insights - GeneDx Holdings Corp. is set to report its second-quarter 2025 results on July 29, with strong expectations based on previous performance and estimates [1][10] Financial Performance - The company reported first-quarter adjusted earnings of 28 cents per share, exceeding the Zacks Consensus Estimate by 154.55%, marking a consistent trend of earnings beats over the past four quarters with an average surprise of 145.82% [1] - The Zacks Consensus Estimate for second-quarter revenues is $84.7 million, indicating a 20.1% increase from the previous year, while the EPS estimate is 10 cents, reflecting a significant year-over-year increase of 190.9% [2] Estimate Revisions - Earnings estimates have increased by 11.1% to 10 cents in the last 30 days, indicating positive sentiment ahead of the earnings announcement [3] Growth Drivers - Revenue growth is anticipated to be driven by Exome and genome tests, with a notable 24% year-over-year increase in test volume during the first quarter, contributing to a 62% revenue increase [4] - The acquisition of Fabric Genomics is expected to enhance GeneDx's capabilities in AI-powered genomic interpretation, facilitating a more comprehensive approach to genomic medicine [5] - The launch of ultraRapid Whole Genome Sequencing is projected to provide faster diagnoses for neonatal and pediatric patients, further contributing to revenue growth [7] Operational Efficiency - The company achieved a 56% growth in adjusted gross profit from continuing operations in the first quarter, leading to a 69% increase in gross margin, with expectations of continued operational efficiency in the second quarter [8] Market Position - GeneDx's strong performance in pediatric neurology and new testing indications is likely to drive outpatient volume growth, positioning the company favorably in the market [9]